Cervical vertebrae | Thanatophoric dysplasia | thanatophoric dysplasia | Spondyloepimetaphyseal dysplasia | spondyloepimetaphyseal dysplasia | Hip dysplasia (human) | Hip dysplasia (disambiguation) | Hip dysplasia | hip dysplasia | Fibromuscular Dysplasia Society of America | Fibromuscular dysplasia | Cervical mucus plug |
The candidate is being developed with a Toll-like receptor 3 (TLR3) agonist adjuvant for multiple indications, including cervical intraepithelial neoplasia (also known as cervical dysplasia or CIN), genital warts, cervical cancer, and head and neck cancers.
Nventa is developing HspE7 in combination with the Toll-like receptor 3 (TLR3) agonist adjuvant Poly-ICLC for multiple indications, including Cervical Intraepithelial Neoplasia (also known as cervical dysplasia or CIN), Genital Warts, Cervical Cancer, and head and neck cancers.